Movement Alert｜Danno Pharma-B Rises 5.94% in Regular Trading, Trading at 250.0 HKD

Market Focus05-27

On May 27, Danno Pharma-B (06872.HK) rose 5.94% in regular trading, trading at 250.0 HKD/share, with trading volume of 9.5374 million HKD.

Danno Pharma (Suzhou) Co., Ltd. is a China-based company principally engaged in the discovery and development of innovative pharmaceutical products. The company focuses on bacterial infections and metabolism-related diseases. Its product pipeline includes Rifatynil (TNP-2198), a new molecular entity candidate for treating Helicobacter pylori infection; Rifaquinone (TNP-2092) injection, a triple-target antibacterial candidate; and TNP-2092 oral formulation, a multi-target antibacterial candidate for intestinal microbiota metabolism-related diseases.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1174985317?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 11:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174985317","market":"us","top_or_hot":-1,"title":"Movement Alert｜Danno Pharma-B Rises 5.94% in Regular Trading, Trading at 250.0 HKD","media":"Market Focus","content":"<p><p>On May 27, Danno Pharma-B (06872.HK) rose 5.94% in regular trading, trading at 250.0 HKD/share, with trading volume of 9.5374 million HKD.</p><p>Danno Pharma (Suzhou) Co., Ltd. is a China-based company principally engaged in the discovery and development of innovative pharmaceutical products. The company focuses on bacterial infections and metabolism-related diseases. Its product pipeline includes Rifatynil (TNP-2198), a new molecular entity candidate for treating Helicobacter pylori infection; Rifaquinone (TNP-2092) injection, a triple-target antibacterial candidate; and TNP-2092 oral formulation, a multi-target antibacterial candidate for intestinal microbiota metabolism-related diseases.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Danno Pharma-B Rises 5.94% in Regular Trading, Trading at 250.0 HKD</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Danno Pharma-B Rises 5.94% in Regular Trading, Trading at 250.0 HKD\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-27 11:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 27, Danno Pharma-B (06872.HK) rose 5.94% in regular trading, trading at 250.0 HKD/share, with trading volume of 9.5374 million HKD.</p><p>Danno Pharma (Suzhou) Co., Ltd. is a China-based company principally engaged in the discovery and development of innovative pharmaceutical products. The company focuses on bacterial infections and metabolism-related diseases. Its product pipeline includes Rifatynil (TNP-2198), a new molecular entity candidate for treating Helicobacter pylori infection; Rifaquinone (TNP-2092) injection, a triple-target antibacterial candidate; and TNP-2092 oral formulation, a multi-target antibacterial candidate for intestinal microbiota metabolism-related diseases.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06872","symbol_name":"丹诺医药-B","start_time":0,"source_url":"","article_id":"1174985317","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174985317","pubTimestamp":1779851218,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 27, Danno Pharma-B (06872.HK) rose 5.94% in regular trading, trading at 250.0 HKD/share, with trading volume of 9.5374 million HKD.Danno Pharma (Suzhou) Co., Ltd. is a China-based company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06872":"丹诺医药-B"},"translate_title":"变动警报|丹诺制药-B在常规交易中升5.94%，报250.0港元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06872":1},"content_text":"On May 27, Danno Pharma-B (06872.HK) rose 5.94% in regular trading, trading at 250.0 HKD/share, with trading volume of 9.5374 million HKD.Danno Pharma (Suzhou) Co., Ltd. is a China-based company principally engaged in the discovery and development of innovative pharmaceutical products. The company focuses on bacterial infections and metabolism-related diseases. Its product pipeline includes Rifatynil (TNP-2198), a new molecular entity candidate for treating Helicobacter pylori infection; Rifaquinone (TNP-2092) injection, a triple-target antibacterial candidate; and TNP-2092 oral formulation, a multi-target antibacterial candidate for intestinal microbiota metabolism-related diseases.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1174985317","isCrawlerRequest":true}